1
|
Kaur P, Sakthivel M, Venkatasamy V, Jogewar P, Gill SS, Kunwar A, Sharma M, Pathni AK, Durgad K, Sahoo SK, Wankhede A, Kumar N, Bharadwaj V, Das B, Chavan T, Khedkar S, Sarode L, Bangar SD, Krishna A, Shivashankar R, Ganeshkumar P, Pragya P, Bhargava B. India Hypertension Control Initiative: Blood Pressure Control Using Drug and Dose-Specific Standard Treatment Protocol at Scale in Punjab and Maharashtra, India, 2022. Glob Heart 2024; 19:30. [PMID: 38524909 PMCID: PMC10959138 DOI: 10.5334/gh.1305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Accepted: 02/05/2024] [Indexed: 03/26/2024] Open
Abstract
Background Hypertension treatment coverage is low in India. A stepwise simple treatment protocol is one of the strategies to improve hypertension treatment in primary care. We estimated the effectiveness of various protocol steps to achieve blood pressure (BP) control in public sector health facilities in Punjab and Maharashtra, India, where the India Hypertension Control Initiative (IHCI) was implemented. Methods We analyzed the records of people enrolled for hypertension treatment and follow-up under IHCI between January 2018 and December 2021 in public sector primary and secondary care facilities across 23 districts from two states. Each state followed a different treatment protocol. We calculated the proportion with controlled BP at each step of the protocol. We also estimated the mean decline in BP pre- and post-treatment. Results Of 281,209 patients initiated on amlodipine 5 mg, 159,292 continued on protocol drugs and came for a follow-up visit during the first quarter of 2022. Of 33,450 individuals who came for the follow-up in Punjab and 125,842 in Maharashtra, 70% and 76% had controlled BP, respectively, at the first step with amlodipine 5 mg. In Punjab, at the second step with amlodipine 10 mg, the cumulative BP control increased to 75%. A similar 5% (76%-81%) increase was seen in the second step after adding telmisartan 40 mg in Maharashtra. Overall, the mean (SD) systolic blood pressure (SBP) decreased by 16 mmHg from 148 (15) mmHg at the baseline in Punjab. In Maharashtra, the decline in the mean (SD) SBP was about 15 mmHg from the 144 (18) mmHg baseline. Conclusion Simple drug- and dose-specific protocols helped achieve a high control rate among patients retained in care under program conditions. We recommend treatment protocols starting with a single low-cost drug and escalating with the same or another antihypertensive drug depending on the cost and availability.
Collapse
Affiliation(s)
- Prabhdeep Kaur
- ICMR - National Institute of Epidemiology Author Institution is Unverified Chennai, IN
| | | | | | - Padmaja Jogewar
- State NCD Cell, Directorate of Health and Family Welfare, Government of Maharashtra, Mumbai, IN
| | - Sandeep S. Gill
- State NCD Cell, Directorate of Health and Family Welfare, Government of Punjab, Chandigarh, IN
| | - Abhishek Kunwar
- Division of Noncommunicable Diseases, WHO Country Office for India, New Delhi, IN
| | - Meenakshi Sharma
- Division of Noncommunicable Diseases, Indian Council of Medical Research (ICMR), New Delhi, IN
| | | | - Kiran Durgad
- IHCI project, WHO Country Office for India, New Delhi, IN
| | | | - Amol Wankhede
- IHCI project, WHO Country Office for India, New Delhi, IN
| | - Navneet Kumar
- IHCI project, State NCD Cell, Chandigarh (Punjab), WHO, IN
| | | | - Bidisha Das
- IHCI project, District NCD Cell, Bhatinda (Punjab), WHO, IN
| | | | - Suhas Khedkar
- IHCI project, District NCD Cell, Satara (Maharashtra), WHO, IN
| | - Lalit Sarode
- IHCI project, District NCD Cell, Nashik (Maharashtra), WHO, IN
| | - Sampada D. Bangar
- Division of Epidemiology and biostatistics, ICMR-National AIDS Research Institute, Pune, IN
| | | | - Roopa Shivashankar
- Division of Noncommunicable Diseases, Indian Council of Medical Research (ICMR), New Delhi, IN
| | | | - Pragati Pragya
- Division of Noncommunicable Diseases, Indian Council of Medical Research (ICMR), New Delhi, IN
| | - Balram Bhargava
- Department of Health Research, MoHFW, Indian Council of Medical Research (ICMR), New Delhi, IN
| |
Collapse
|
2
|
Sahoo SK, Pathni AK, Krishna A, Sharma B, Cazabon D, Moran AE, Hering D. Financial implications of protocol-based hypertension treatment: an insight into medication costs in public and private health sectors in India. J Hum Hypertens 2023; 37:828-834. [PMID: 36271130 PMCID: PMC10471490 DOI: 10.1038/s41371-022-00766-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2022] [Revised: 09/20/2022] [Accepted: 09/30/2022] [Indexed: 11/10/2022]
Abstract
Hypertension is a major public health challenge in low- and middle-income countries (LMICs) and calls for large-scale effective hypertension control programs. Adoption of drug and dose-specific treatment protocols recommended by the World Health Organization-HEARTS Initiative is key for hypertension control programs in LMICs. We estimated the annual medication cost per patient using three such protocols (protocol-1 and protocol-2 with Amlodipine, Telmisartan, using add-on doses and different drug orders, adding Chlorthalidone; protocol-3 with a single-pill combination (SPC) of Amlodipine/Telmisartan with dose up-titration, and addition of Chlorthalidone, if required) in India. The medication cost was simulated with different hypertension control assumptions for each protocol and calculated based on prices in the public and private sectors in India. The estimated annual medication cost per patient for protocol-1 and protocol-2 was $33.88-58.44 and $51.57-68.83 for protocol-3 in the private sector. The medication cost was lower in the generic stores ($5.78-9.57 for protocol-1 and protocol-2, and $7.35-9.89 for protocol-3). The medication cost for patients was the lowest ($2.05-3.89 for protocol-1 and protocol-2, and $2.94-3.98 for protocol-3) in the public sector. At less than $4 per patient per annum, scaling up a hypertension control program with specific treatment protocols is a potentially cost-effective public health intervention. Expanding low-cost generic retail networks would extend affordability in the private sector. The cost of treatment with SPC is comparable with non-SPC protocols and can be adopted in a public health program considering the advantage of simplified logistics, reduced pill burden, improved treatment adherence, and blood pressure control.
Collapse
Affiliation(s)
| | | | | | | | | | - Andrew E Moran
- Resolve to Save Lives, New York, NY, USA
- Columbia University Irving Medical Center, New York, NY, USA
| | - Dagmara Hering
- Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland.
| |
Collapse
|
3
|
Hegde A, Patel H, Laxmeshwar C, Phalake A, Khungar Pathni A, Gandhi R, Moran AE, Kannure M, Sharma B, Jondhale V, Surendran S, Vijayan S. Delivering hypertension care in private-sector clinics of urban slum areas of India: the Mumbai Hypertension Project. J Hum Hypertens 2023; 37:767-774. [PMID: 36153383 PMCID: PMC9510164 DOI: 10.1038/s41371-022-00754-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Revised: 08/16/2022] [Accepted: 09/06/2022] [Indexed: 11/08/2022]
Abstract
In India, the private sector provides 70% of the total outpatient medical care. This study describes the Mumbai Hypertension Project, which aimed to deliver a standard hypertension management package in private sector clinics situated in urban slums. The project was conducted in two wards (one "lean" and one "intensive") with 82 private providers in each. All hypertensive patients received free drug vouchers, baseline serum creatinine, adherence support, self-management counseling and follow-up calls. In the intensive-ward, project supported hub agents facilitated uptake of services. A total of 13,184 hypertensive patients were registered from January 2019 to February 2020. Baseline blood pressure (BP) control rates were higher in the intensive-ward (30%) compared with the lean-ward (13%). During the 14-month project period, 6752 (51%) patients followed-up, with participants in the intensive-ward more likely to follow-up (aOR: 2.31; p < 0.001). By project end, the 3-6-month cohort control rate changed little from baseline-29% for intensive ward and 14% for lean ward. Among those who followed up, proportion with controlled BP increased 13 percentage points in the intensive ward and 16 percentage points in the lean ward; median time to BP control was 97 days in the intensive-ward and 153 days in lean-ward (p < 0.001). Despite multiple quality-improvement interventions in Mumbai private sector clinics, loss to follow-up remained high, and BP control rates only improved in patients who followed up; but did not improve overall. Only with new systems to organize and incentivize patient follow-up will the Indian private sector contribute to achieving national hypertension control goals.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Andrew E Moran
- Resolve to Save Lives, New York, NY, USA
- Columbia University Irving Medical Centre, New York, NY, USA
| | | | | | | | | | | |
Collapse
|
4
|
Cazabon D, Farrell M, Gupta R, Joseph L, Pathni AK, Sahoo S, Kunwar A, Elliott K, Cohn J, Frieden TR, Moran AE. A simple six-step guide to National-Scale Hypertension Control Program implementation. J Hum Hypertens 2021; 36:591-603. [PMID: 34702957 PMCID: PMC8545775 DOI: 10.1038/s41371-021-00612-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Revised: 08/23/2021] [Accepted: 09/14/2021] [Indexed: 11/09/2022]
Abstract
Hypertension is the leading single preventable risk factor for death worldwide, and most of the disease burden attributed to hypertension weighs on low-and middle-income countries. Effective large-scale public health hypertension control programs are needed to control hypertension globally. National programs can follow six important steps to launch a successful national-scale hypertension control program: establish an administrative structure and survey current resources, select a standard hypertension treatment protocol, ensure supply of medication and blood pressure devices, train health care workers to measure blood pressure and control hypertension, implement an information system for monitoring patients and the program overall, and enroll and monitor patients with phased program expansion. Resolve to Save Lives, an initiative of global public health organization Vital Strategies, and its partners organized these six key steps and materials into a structured, stepwise guide to establish best practices in hypertension program design, launch, maintenance, and scale-up.
Collapse
Affiliation(s)
- Danielle Cazabon
- Resolve to Save Lives, an initiative of Vital Strategies, New York, NY, USA.
| | - Margaret Farrell
- Resolve to Save Lives, an initiative of Vital Strategies, New York, NY, USA
| | - Reena Gupta
- University of California San Francisco, San Francisco, CA, USA
| | - Lindsay Joseph
- Resolve to Save Lives, an initiative of Vital Strategies, New York, NY, USA
| | | | - Swagata Sahoo
- Resolve to Save Lives, an initiative of Vital Strategies, New Delhi, India
| | - Abhishek Kunwar
- World Health Organization Country Office for India, New Delhi, India
| | - Kate Elliott
- Resolve to Save Lives, an initiative of Vital Strategies, New York, NY, USA
| | - Jennifer Cohn
- Resolve to Save Lives, an initiative of Vital Strategies, New York, NY, USA.,Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
| | - Thomas R Frieden
- Resolve to Save Lives, an initiative of Vital Strategies, New York, NY, USA
| | - Andrew E Moran
- Resolve to Save Lives, an initiative of Vital Strategies, New York, NY, USA.,Columbia University Irving Medical Center, New York, NY, USA
| |
Collapse
|
5
|
Cohn J, Kostova D, Moran AE, Cobb LK, Pathni AK, Bisrat D. Blood from a stone: funding hypertension prevention, treatment, and care in low- and middle-income countries. J Hum Hypertens 2021; 35:1059-1062. [PMID: 34331004 PMCID: PMC8654676 DOI: 10.1038/s41371-021-00583-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Revised: 07/03/2021] [Accepted: 07/19/2021] [Indexed: 11/18/2022]
Affiliation(s)
- Jennifer Cohn
- Resolve to Save Lives, New York, NY, United States. .,Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, PA, United States.
| | - Deliana Kostova
- Division of Global Health Protection, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, United States
| | - Andrew E Moran
- Resolve to Save Lives, New York, NY, United States.,Division of General Medicine, Department of Medicine, Columbia University, New York, NY, United States
| | - Laura K Cobb
- Resolve to Save Lives, New York, NY, United States
| | | | | |
Collapse
|
6
|
Negi S, Neupane D, Sahoo SK, Mahajan T, Swaroop K, Moran AE, Sharma B, Pathni AK. Prices of combination medicines and single-molecule antihypertensive medicines in India's private health care sector. J Clin Hypertens (Greenwich) 2020; 23:738-743. [PMID: 33369089 PMCID: PMC8678655 DOI: 10.1111/jch.14143] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Revised: 11/28/2020] [Accepted: 11/30/2020] [Indexed: 12/12/2022]
Abstract
More than half of patients with hypertension require two or more medicines to control blood pressure. Combinations of anti‐hypertensive medicines are available as Single Pill Combinations (SPCs) or Single Agent Pills (SAPs). SPCs of two or more anti‐hypertensive medicines facilitate simpler dosing schedules, decrease pill burden, increase adherence to medicine, and simplify procurement and distribution. Despite this, equivalent combinations of separate pills (SAPs) are often prescribed instead of SPCs under the assumption that SAPs are priced lower. This study compared prices of anti‐hypertensive SPCs and equivalent SAPs in the private health care sector of India. High sales volume anti‐hypertensive SPCs and SAPs were selected from 2018 private sector pharmaceutical sales data. SPCs and SAPs price information was collected from online pharmacy websites between November 2019 and January 2020. Anti‐hypertensive SPCs represent approximately 39.1% of India's private sector anti‐hypertensive drug market. Multiple manufacturers produce the same top‐selling SPCs, suggesting a viable and competitive market. A comparison of SPCs and SAPs across different manufacturers showed that the lowest prices of both SPCs and the sum of component SAPs were nearly identical across different manufacturers. An analysis of dual‐drug SPCs and SAPs by the same manufacturer showed that most manufacturers (five of six) had priced their SPCs higher than SAPs. These observations suggest that the price of SPCs could be lowered to match the combined price of the component SAPs, and manufacturing costs and market forces do not present a barrier to the implementation of anti‐hypertensive SPCs.
Collapse
Affiliation(s)
- Sagri Negi
- Resolve to Save Lives, New York, NY, USA
| | - Dinesh Neupane
- Lancet Commission on Hypertension Group, London, UK.,Department of Epidemiology, Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, USA
| | | | - Tanushree Mahajan
- Department of Analytics, IQVIA Consulting and Information Services, New Delhi, India
| | - Kishan Swaroop
- Department of Analytics, IQVIA Consulting and Information Services, New Delhi, India
| | - Andrew E Moran
- Resolve to Save Lives, New York, NY, USA.,Columbia University Irving Medical Center, New York, NY, USA
| | | | | |
Collapse
|
7
|
Pathni AK, Pathni R. Global Viral Hepatitis Strategy: Issues with Hepatitis B Immunization in India. Indian J Community Health 2017. [DOI: 10.47203/ijch.2017.v29i03.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Hepatitis B vaccination, a key component of the recently adopted Global Viral Hepatitis Strategy, has been plagued by various issues since its introduction under the National immunization program in India. While the concerns relating to the inclusion of the vaccine under the Universal Immunization Program, the vaccination strategies adopted and prevention of mother to child transmission of hepatitis B have been largely resolved, data from recent research has underscored the need for regular monitoring of immunological and epidemiological outcomes of the vaccine. Controversies surrounding the safety and efficacy of the recently introduced combination pentavalent vaccine have highlighted that besides reinforcing surveillance of adverse events following immunization in the public sector, the private health sector in the country needs to be supported in this activity by increasing awareness and strengthening public-private collaboration
Collapse
|
8
|
Das A, Pathni AK, Narayanan P, George B, Morineau G, Saidel T, Prabhakar P, Deshpande GR, Gangakhedkar R, Mehendale S, Risbud A. High rates of reinfection and incidence of bacterial sexually transmitted infections in a cohort of female sex workers from two Indian cities: need for different STI control strategies? Sex Transm Infect 2012. [PMID: 23196329 PMCID: PMC3582065 DOI: 10.1136/sextrans-2012-050472] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Abstract
Background Female sex workers (FSWs) in India are provided a standardised package of clinical interventions for management of sexually transmitted infections (STIs). A study was conducted among FSWs at known high STI prevalence sites to determine the effectiveness of the service package. Methods A cohort of FSW clinic attendees in two cities, Hyderabad and Mumbai, were enrolled and followed up from October 2008 to November 2009. At each visit, behavioural and clinical data were obtained and vaginal swabs collected for laboratory testing of cervical infections (gonorrhoea and chlamydia). Results 417 participants were enrolled, of whom 360 attended at least a follow-up visit. Prevalence of cervical infections did not change between the baseline and final visits (27.7% and 21.3% respectively, p=0.08) in spite of presumptive treatment at baseline and syndromic management at all visits. The proportion of asymptomatic cervical infections increased from 36% at baseline to 77% at the final visit. Incidence rate of cervical infections was high (85.6/100 person years) and associated with a prevalent cervical infection at baseline (HR=2.7, p<0.001) and inconsistent condom use with non-commercial partners (HR=2.5, p=0.014). Conclusions High rates of STIs persisted despite the interventions due to poor condom use, minimal partner treatment, and high prevalence and incidence of STIs with a large proportion of asymptomatic infections. High-prevalence FSW sites in India need to design more effective partner treatment strategies and consider increasing the frequency of presumptive treatment as a temporary measure for quickly reducing STI prevalence, with renewed emphasis on consistent condom use with all partners.
Collapse
Affiliation(s)
- Anjana Das
- STI Capacity Raising, FHI 360, New Delhi 110016, India.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Pathni AK, Chauhan LS. HIV/TB in India: a public health challenge. J Indian Med Assoc 2003; 101:148-9. [PMID: 14603958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
The impact of HIV/AIDS epidemic on the epidemiology of TB worldwide is being noted with growing concern. Patients with HIV are more susceptible to opportunistic diseases including TB. The risk of development of TB in HIV-infected patients in India is 6.9/100 person-years compared to a 10% lifetime risk of developing TB in an HIV negative individual with Mycobacterium tuberculosis. Treatment with DOTS significantly prolongs the life of HIV-infected persons with TB. The Government of India emphasised the need for strengthening collaboration between TB and AIDS control programmes for better management of HIV-infected patients with TB. Areas with higher prevalence of HIV infection have been prioritised the RNTCP coverage and most are already implementing the RNTCP. The basic purpose of HIV-TB programme co-ordination is to ensure optimal synergy between the two programmes for prevention and control of both the diseases.
Collapse
Affiliation(s)
- A K Pathni
- National AIDS Control Organisation, New Delhi 110 001
| | | |
Collapse
|